The hypoxic ventilatory response (HVR) at sea level (SL) is moderately predictive of the change in pulmonary artery systolic pressure (PASP) to acute normobaric hypoxia. However, because of progressive changes in the chemoreflex control of breathing and acid-base balance at high altitude (HA), HVR at SL may not predict PASP at HA. We hypothesized that resting peripheral oxyhemoglobin saturation (SpO 2 ) at HA would correlate better than HVR at SL to PASP at HA. In 20 participants at SL, we measured normobaric, isocapnic HVR (L/min·-%SpO 2 -1 ) and resting PASP using echocardiography.
Abstract:
The hypoxic ventilatory response (HVR) at sea level (SL) is moderately predictive of the change in pulmonary artery systolic pressure (PASP) to acute normobaric hypoxia. However, because of progressive changes in the chemoreflex control of breathing and acid-base balance at high altitude (HA), HVR at SL may not predict PASP at HA. We hypothesized that resting peripheral oxyhemoglobin saturation (SpO 2 ) at HA would correlate better than HVR at SL to PASP at HA. In 20 participants at SL, we measured normobaric, isocapnic HVR (L/min·-%SpO 2 -1 ) and resting PASP using echocardiography.
Both resting SpO 2 and PASP measures were repeated on day 2 (n=10), days 4-8 (n=12), and 2-3 weeks (n=8) after arrival at 5050m. These data were also collected at 5050m on life-long HA residents (Sherpa; n=21). Compared to SL, SpO 2 decreased from 98.6 to 80.5% (P<0.001), while PASP increased from 21.7 to 34.0mmHg (P<0.001) after 2-3 weeks at 5050m. Isocapnic HVR at SL was not related to SpO 2 or PASP at any time point at 5050m (all P>0.05). Sherpa had lower PASP (P<0.01) than lowlanders on days 4-8 despite similar SpO 2 . Upon correction for hematocrit, Sherpa PASP was not different from lowlanders at SL, but lower than lowlanders at all HA time points. At 5050m, whilst SpO 2 was not related to PASP in lowlanders at any point (all R 2 =<0.05; P>0.50), there was a weak relationship in the Sherpa (R 2 =0.16; P=0.07). We conclude that neither HVR at SL nor resting SpO 2 at HA correlates with elevations in PASP at HA.
Introduction:
The initial increase in ventilation in response to hypoxia (i.e. hypoxic ventilatory response; HVR) is highly variable 1 . In response to a decreased partial pressure of oxygen (PO 2 ) at high altitude (HA), pulmonary artery pressure (PAP) increases primarily through hypoxic pulmonary vasoconstriction (HPV) 2 . In some studies, a blunted HVR is characteristic of high altitude pulmonary edema (HAPE)
susceptible subjects who exhibit marked elevations in PAP [3] [4] [5] [6] [7] [8] [9] . The latter findings highlight a link between HVR and PAP at altitude.
Animal studies have clearly demonstrated that higher peripheral chemoreceptor responsiveness attenuates HPV 10, 11 . For example, following mechanical ventilation of the lungs with 100% N 2 , stimulation of the carotid chemoreceptors via arterial hypoxemia reduces pulmonary vascular resistance in cats and dogs 12, 13 . This neural modulation of PAP in hypoxia has been studied recently in humans by interpolating the pulmonary artery systolic pressure (PASP) response to hypoxia at a specific peripheral oxyhemoglobin saturation (SpO 2 =85%). 14 Between-individual variability in HVR (indicative of peripheral chemoreceptor responsiveness) at SL was moderately correlated (R 2 =0.38) with PASP in normobaric hypoxia. 14 This finding is consistent with the aforementioned reports linking HVR to HAPE susceptibility, and HAPE to excessive HPV. Furthermore, individuals with a blunted HVR will consequently have a lower alveolar PO 2 and thus a greater stimulus to HPV at any given altitude 14 .
However, the issue with extrapolating variability in HVR at SL to predict changes in PAP at HA is that, in addition to acid-base adjustments, HVR represents a reflex arc with three components: (1) afferent input, (2) central integration, and (3) efferent output 15 , all of which are likely changing, resulting in an overall change in HVR at HA 16, 17 . Due to the myriad of physiologic changes at HA related to the HVR [18] [19] [20] and HPV 21 , we hypothesized that resting SpO 2 at HA would correlate better than variability in HVR at SL to PASP at HA (i.e., by virtue of SpO 2 reflecting alveolar PO 2 and hence HPV). We also reasoned that chronic adaptation to HA, as seen in the Sherpa, would result in higher resting SpO 2 and lower PASP than that of lowlanders at HA. Nepal and seven nights in Kathmandu (~1400m), participants flew to Lukla (2800m) and began an 8-11
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day ascent to the Pyramid Research Laboratory (5050m). A cautious ascent profile was adopted, with ≤700m net gain per day and at least two days with no net change in altitude. Participants were given low-dose acetazolamide (125mg, oral) twice per day as an acute mountain sickness prophylactic 22 .
Acetazolamide was discontinued at ~4300m (Pheriche), at least one day before ascending to the laboratory, to allow sufficient time (e.g., ≥48 hours) for the drug to clear participants' system prior to the first data collection session at 5050m 23, 24 . Previously, pre-treatment of acetazolamide has resulted in an almost negligible difference of PASP (~2mmHg; no statistical analyses were performed) 48hours after final drug treatment when compared to individuals that received placebo treatment 25 . Although unlikely to alter our findings, we were unable to rule out the possibility of persisting physiological sequelae secondary to acetazolamide treatment during our day two testing. Participants spent 1 to 3 days at Pheriche before the final ascent. Expedition members participating in this study had a minimum of 48h between this and other studies involving pharmaceutical interventions or exercise, to minimize contamination. Some of the data presented here (e.g., chemosensitivity responses, pulmonary pressures)
have been reported previously in other studies from these expeditions [26] [27] [28] [29] ; however, the research question addressed here is distinct, and combining data from these two expeditions provides a novel data set, with greater power to address the research question 30 .
Transthoracic Echocardiography
All echocardiographic images were recorded on a commercially available portable ultrasound system with the addition of right atrial pressure estimated from the collapsibility of the inferior vena cava on inspiration 31 . Heart rate was recorded via 3-lead electrocardiogram.
Chemoreflex testing
The respiratory chemoreflex responses to both hypoxia (an index of peripheral chemoreflex sensitivity; HVR) and hypercapnia (an index of central chemoreflex sensitivity; HCVR) were assessed at SL in the 2008 and 2012 studies; however, these tests differed slightly between investigations. Specifically, in the 2008 experiments, isocapnic hypoxia was induced for approximately 4-9 minutes via a 6-L rebreathing bag and soda lime reservoir. The isocapnic hypoxia was terminated when either: 1) partial pressure of end-tidal oxygen (P ET O 2 ) reached 45mmHg at SL; 2) ventilation (V E ) exceeded 100L/min; or 3) the participant reached the end of their tolerance. In the 2012 experiments, isocapnic hypoxia (P ET O 2 = 47mmHg) was maintained over 10 minutes via end-tidal forcing, as described in depth elsewhere 29, 32 .
Despite the different methods, in a sub-group of participants (n=6) who underwent both tests, the peak HVR between tests was comparable (R 2 =0.46; P<0.05) and not significantly different from one another (P=0.6), indicating they both reflected similar chemoreflex phenomena. In 2012, a subgroup (n=8) of participants at SL underwent 10 minutes of poikilocapnic hypoxia (11% O 2 ) to simulate 5050m.
Although acute poikilocapnic hypoxia testing is more complicated than the commonly used isocapnic hypoxic tests, due to the interactive effects of hypoxia and concomitant hypocapnia, they are more representative of the uncontrolled breathing environment at HA, and therefore, more applicable to such scenarios.
In 2008, HCVR was assessed from a 4-min steady state hyperoxic hypercapnia gas mixture (7% CO 2 ;
93% O 2 ) after a 5-min room air baseline. In 2012, HCVR was assessed using end-tidal forcing where the partial pressure of end-tidal carbon dioxide (P ET CO 2 ) was clamped initially at baseline and then elevated in a stepwise fashion at +5, +10, and +15mmHg from individual baseline values while P ET O 2 was maintained at individual baseline values (~100mmHg). In a sub-group of participants (n=7) who underwent both tests, the relationship (R 2 ) between HCVR tests was 0.53 (P<0.01).
In both the 2008 and 2012 experiments, all respiratory parameters were acquired at 200Hz using an analog-to-digital converter (PowerLab/16SP ML 880; ADInstruments, Colorado Springs, CO, USA)
interfaced with a personal computer and analyzed with commercially available software (LabChart, ADInstruments). Throughout all procedures, participants breathed through a mouthpiece (with noseclip) or facemask with an attached bacteriological filter, and a two-way non-rebreathing valve (2600 series, Hans Rudolph, Shawnee, KS, USA). Respired gas was sampled at the mouth and analyzed for P ET O 2 and P ET CO 2 by a calibrated gas analyzer (ML206; ADInstruments). Respiratory flow was measured near the mouth using a pneumotachograph (HR 800L, HansRudolph) and a differential pressure amplifier (ML141, ADInstruments).
Calculations
For the 2008 studies, isocapnic HVR was calculated as the slope of the linear regression between V E and SpO 2 , while HCVR was calculated as ΔV E /ΔP ET CO 2 from baseline to steady state. For the 2012 studies, isocapnic HVR was calculated as ΔV E /ΔSpO 2 from baseline to the peak ventilation during hypoxia. Peak poikilocapnic HVR was calculated in a similar manner, while delayed poikilocapnic HVR was calculated as ΔV E /ΔSpO 2 from baseline to the average of minutes 10-15 of hypoxia. The HCVR was calculated as the linear regression slope between V E and P ET CO 2 .
To account for differences in hematocrit (HCT) between groups we estimated PASP after correction of HCT to sea level values (45%). First, we calculated pulmonary vascular resistance (PVR) in all of our subjects using the following equation 31 :
Where TRV is tricuspid regurgitation velocity (m/s), and RVOT VTI is the right ventricular outflow tract velocity time integral (cm), and PVR is pulmonary vascular resistance expressed in woods units.
Once this was determined for both lowlanders and Sherpa at high altitude, we calculated PVR at a HCT of 45% in all individuals using the following equation 33 :
Where ϕ represents the hematocrit at HA. As pressure is proportional to resistance, we infer the calculated %change in PVR to be representative of the %change effect of hematocrit on PASP, and as 
Statistical Analyses
Comparison of lowlanders at SL, day two, day five, and 2-3 weeks at altitude, as well as Sherpa were performed using a 1-factor ANOVA. The relationship between variables (SpO 2 , HVR, HCVR, & PASP)
was assessed using least squares linear regression following conformation of a Gaussian distribution.
Alpha was set a priori to 0.05. All statistical analyses were performed using Prism (Version 5.0b, 2008) and SPSS (IBM Statistics, Version 21, 2012).
Results
Baseline Characteristics
Consistent with previous reports of HVR and HCVR at 4300m 34 and in Sherpa (R 2 =0.16; P=0.07). On examination of the group regressions, the slopes for lowlanders on day two, day five, after 2-3 weeks acclimatization and Sherpa were -0.29, 0.67, -0.49 and -0.74mmHg · -%SpO 2 -1 , respectively (Figure 2 ).
Discussion
The primary finding of this study is the lack of correlation between both peripheral and central chemosensitivity at SL and PASP at HA, contrary to previous findings during SL hypoxia.
14 Furthermore, at any time point, there was no relationship between HA SpO 2 and resting PASP at 5050m
in SL dwellers. Consistent with our second hypothesis, Sherpa had higher SpO 2 and lower PASP than lowlanders on day two at HA. Early acclimatization eliminated the difference in SpO 2 between Sherpa and lowlanders while PASP was generally lower in the native highlanders.
Changes in peripheral chemoreceptor responsiveness 19, 36, 37 , central processing 18, 20, 38 , and the consequent efferent output 18 all effect the ventilatory response to hypoxia at altitude 16, 17 . The further effect of changes in acid-base balance, as well as the complex nature of breathing at HA have been reviewed in detail 15 . Therefore, although SL HVR has been correlated with PASP during normobaric hypoxia (SpO 2 =85%; n=15) 14 , the lack of correlation (of both isocapnic and poikilocapnic HVR) to PASP at HA is perhaps not surprising due to the aforementioned changes, in addition to changes in lung diffusion capacity 39 , which occur upon exposure to altitude. Moreover, as HVR rapidly increases within the first week of exposure to HA 16, 17 , and full ventilatory acclimatization may take up to 4-6 weeks at 5050m 15 , it is further not surprising that SL HVR was unrelated to PASP at all HA time points.
Although a blunted HVR has been reported in some studies to related to HAPE susceptibility 40,41 , we did not include any AMS/HAPE susceptible subjects by design and ensured safe ascent and acclimatization.
As most studies derive their relationships via the use of two distinct phenotypes (i.e. AMS susceptible and non-susceptible who often have a blunted and brisk HVR [40] [41] [42] [43] , respectively), having a singular phenotype within our participant group may preclude any relationship between HVR and PASP.
However, this does not undermine the significance that biological variability in SL HVR does not predict the marked variability in PASP at HA in a homogenous group.
An inverse relationship between SpO 2 and PAP was reported as early as 1957 at 4540m 44 50 , and blood viscosity 29 . To provide insight into this latter point, we corrected both lowlander and Sherpa PASP values to a sea level HCT (45%). After correction, PASP in Sherpa fell within sea level norms at ~24mmHg therefore indicating that hematocrit and subsequently viscosity are predominantly responsible for their elevated PASP at 5050m. This further provides evidence suggesting a differential regulation of PASP between lowlanders and high altitude natives, and indicates that we and others 28, 29, 48 have likely underestimated the difference in HPV between lowlanders and Sherpa without consideration of changes in HCT 33 .
In conclusion, as the multiple factors regulating breathing differ between SL and HA, the utility of SL chemoreflex tests, both poikilocapnic and isocapnic, to predict changes in PASP at HA is limited in otherwise healthy individuals.
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